TransCode Therapeutics
Stock Forecast, Prediction & Price Target
TransCode Therapeutics Financial Estimates
TransCode Therapeutics Revenue Estimates
TransCode Therapeutics EBITDA Estimates
TransCode Therapeutics Earnings per Share Estimates
Passed | Analyst forecast | ||||||
---|---|---|---|---|---|---|---|
Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $0 N/A | $0 0% | $0 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $9.7M Low: $9.7M High: $9.7M avg. 0% | Avg: $9.9M Low: $9.9M High: $9.9M avg. 2.06% |
Net Income
% change YoY
| $-6.93M N/A | $-35.12M -406.30% | $-18.54M 47.20% | Avg: $-119.93K Low: $-119.93K High: $-119.93K avg. 99.35% | Avg: $-84.13K Low: $-84.13K High: $-84.13K avg. 29.85% | Avg: $-82.34K Low: $-82.34K High: $-82.34K avg. 2.12% | Avg: $-69.81K Low: $-69.81K High: $-69.81K avg. 15.21% |
EBITDA
% change YoY
| $-5.82M N/A | $-17.46M -199.61% | $-17.97M -2.90% | Avg: $0 Low: $0 High: $0 avg. 100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% |
EPS
% change YoY
| -$658.8 N/A | -$2,195.62 -233.27% | -$103.61 95.28% | Avg: -$0.67 Low: -$0.67 High: -$0.67 avg. 99.35% | Avg: -$0.47 Low: -$0.47 High: -$0.47 avg. 29.85% | Avg: -$0.46 Low: -$0.46 High: -$0.46 avg. 2.12% | Avg: -$0.39 Low: -$0.39 High: -$0.39 avg. 15.21% |
Operating Expenses
% change YoY
| $5.87M N/A | $17.58M 199.43% | $19.41M 10.42% | Avg: $0 Low: $0 High: $0 avg. -100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% |
FAQ
What is TransCode Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 36.63% in 2025-2028.
We have gathered data from 1 analysts. Their low estimate is -119.93K, average is -119.93K and high is -119.93K.
What is TransCode Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 0.51% in 2025-2028.
We have gathered data from N/A analysts. Their low revenue estimate is N/A, average is N/A and high is N/A.
What is TransCode Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 36.63% in 2025-2028.
We have gathered data from 1 analysts. Their low earnings per share estimate is -$0.67, average is -$0.67 and high is $-0.67.